Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Praxis Precision Medicines (PRAX) Cash from Investing Activities (2022 - 2025)

Praxis Precision Medicines (PRAX) has 4 years of Cash from Investing Activities data on record, last reported at -$328.4 million in Q4 2025.

  • For Q4 2025, Cash from Investing Activities fell 2907.79% year-over-year to -$328.4 million; the TTM value through Dec 2025 reached -$311.1 million, down 25.21%, while the annual FY2025 figure was -$311.1 million, 25.21% down from the prior year.
  • Cash from Investing Activities reached -$328.4 million in Q4 2025 per PRAX's latest filing, down from $50.4 million in the prior quarter.
  • Across five years, Cash from Investing Activities topped out at $50.4 million in Q3 2025 and bottomed at -$328.4 million in Q4 2025.
  • Average Cash from Investing Activities over 4 years is -$28.3 million, with a median of $5.0 million recorded in 2023.
  • Peak YoY movement for Cash from Investing Activities: surged 497.66% in 2023, then plummeted 21736.0% in 2024.
  • A 4-year view of Cash from Investing Activities shows it stood at $22.6 million in 2022, then crashed by 100.22% to -$50000.0 in 2023, then tumbled by 21736.0% to -$10.9 million in 2024, then plummeted by 2907.79% to -$328.4 million in 2025.
  • Per Business Quant database, its latest 3 readings for Cash from Investing Activities were -$328.4 million in Q4 2025, $50.4 million in Q3 2025, and $17.9 million in Q2 2025.